Revelation Biosciences, Inc. (REVB) |
|
1.3 -0.05 (-3.7%)
|
03-31 16:00 |
|
Open: |
1.32 |
Pre. Close: |
1.35 |
|
High:
|
1.39 |
Low:
|
1.29 |
|
Volume:
|
134,784 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:42 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.37 One year: 2.92 |
| Support: |
Support1: 1.26 Support2: 1.05 |
| Resistance: |
Resistance1: 2.03 Resistance2: 2.5 |
| Pivot: |
1.47  |
| Moving Average: |
MA(5): 1.36 MA(20): 1.59
MA(100): 5.71 MA(250): 14.28 |
| MACD: |
MACD(12,26): -0.6  Signal(9): -0.8 |
| Stochastic oscillator: |
%K(14,3): 7.5 %D(3): 9.5 |
| RSI: |
RSI(14): 26 |
| 52-week: |
High: 67.9 Low: 0.42 |
| Average Vol(K): |
3-Month: 273 (K) 10-Days: 158 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 25.1%. Bollinger Bands are 79.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.39 - 1.4 |
1.4 - 1.41 |
|
Low:
|
1.27 - 1.28 |
1.28 - 1.29 |
|
Close:
|
1.28 - 1.3 |
1.3 - 1.31 |
|
Company Description |
|
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California. |
Headline News |
Thu, 30 Mar 2023
Revelation Biosciences Inc. Announces Financial Results for the ... - Business Wire
Wed, 22 Mar 2023
Should You Buy Revelation Biosciences Inc (REVB) Stock Wednesday? - InvestorsObserver
Wed, 15 Mar 2023
Is Revelation Biosciences Inc (REVB) Stock About to Get Hot Wednesday? - InvestorsObserver
Mon, 06 Mar 2023
Revelation Biosciences Inc. to Participate in a Fireside Chat at the ... - Business Wire
Tue, 14 Feb 2023
Is Revelation Biosciences Inc (REVB) Stock Worth a Buy Tuesday? - InvestorsObserver
Thu, 09 Feb 2023
Revelation Biosciences Inc. Announces Pricing of $15.6 Million ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
4 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
59.1 (%) |
|
% Held by Institutions
|
4.4 (%) |
|
Shares Short
|
103 (K) |
|
Shares Short P.Month
|
31 (K) |
Stock Financials |
|
EPS
|
-16.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-135.4 |
|
Return on Equity (ttm)
|
-458.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.78 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-13 (M) |
|
Levered Free Cash Flow
|
-5 (M) |
Stock Valuations |
|
PE Ratio
|
-0.08 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.39 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.36 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
